Abstract: Modules, devices, systems and methods for measuring or detecting cysteine and/or methionine metabolite levels in a sample from a subject are disclosed. Various embodiments of the present invention concern modules, devices, systems and methods for prognosing or diagnosing cancer, for example, prostate, colon, ovarian or breast cancer; predicting the risk or probability of cancer recurrence; and/or for predicting, detecting and/or monitoring cystinuria or cystine stone disease.

Abstract: Modules, devices, systems and methods for measuring or detecting cysteine and/or methionine metabolite levels in a sample from a subject are disclosed. Various embodiments of the present invention concern modules, devices, systems and methods for prognosing or diagnosing cancer, for example, prostate, colon, ovarian or breast cancer; predicting the risk or probability of cancer recurrence; and/or for predicting, detecting and/or monitoring cystinuria or cystine stone disease.

Abstract: The invention relates to the use of enzymes, nanorods, and nanoelectronic devices to detect cysteine level in a patient sample and relates to the use of the detected cysteine level to predict cancer recurrence in the patient and to prescribe and/or administer an appropriate therapy to a subject. The invention is directed to systems and methods of detecting cysteine level in a sample from a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention further comprises prescribing and/or administering an appropriate therapy to a subject based on the predicted probability of recurrence.

Abstract: The invention relates to the use of enzymes and nanorods to detect cysteine level in a patient sample and relates to the use of the detected cysteine level to predict cancer recurrence in the patient. The invention is directed to systems and methods of detecting cysteine level in a sample from a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. This invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject and treating the subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage.